COMMUNIQUÉS West-GlobeNewswire

Le KFSH&RC s’efforce d’être un pionnier dans la valorisation optimale des dépenses de santé
12/05/2024
Le Dr Al Fayyadh à l’Université de Harvard : « Nous nous reposons sur la technologie pour relever les enjeux de santé à l’échelle mondiale » RIYAD, Arabie saoudite, 12 mai 2024 (GLOBE NEWSWIRE) -- Le Dr Majid Al Fayyadh [...]
iTeos fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024
11/05/2024
- Le doublet belrestotug + dostarlimab a dépassé les critères d’efficacité prédéfinis pour une activité cliniquement pertinente constatée lors d’une évaluation intérimaire de Phase 2 sur GALAXIES Lung-201 - Une [...]
Le KFSH&RC repousse les limites et célèbre une année couronnée de succès pour trois de ses centres d’excellence
11/05/2024
RIYAD, Arabie saoudite, 11 mai 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre, ci-après « KFSH&RC », soit l’hôpital spécialisé et centre de recherche King Faisal, célèbre une année [...]
iTeos Therapeutics annonce une offre directe enregistrée de 120 millions de dollars
11/05/2024
- Pilotage assuré par les investisseurs actuels RA Capital Management et Boxer Capital - Prix d’achat fixé à 17,50 dollars, soit une prime d’environ 44 % par rapport à la dernière clôture - Renforcement du bilan avec [...]
KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value
11/05/2024
Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) -- Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research [...]
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10/05/2024
Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trials Bolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio [...]
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/05/2024
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock [...]
Evaxion Receives Nasdaq Notification
10/05/2024
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today [...]
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
10/05/2024
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial [...]
Atrion Reports First Quarter 2024 Results
10/05/2024
ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million [...]
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
10/05/2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/05/2024
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/05/2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Longeveron Announces Board of Directors Planned Transitions
10/05/2024
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been [...]
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
10/05/2024
$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam [...]
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
10/05/2024
LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated [...]
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10/05/2024
Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose [...]
NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
10/05/2024
EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Le King Faisal Specialist Hospital & Research Centre chef de file de la transformation du secteur de la santé en Arabie saoudite
10/05/2024
RIYAD, Arabie saoudite, 10 mai 2024 (GLOBE NEWSWIRE) -- Université de Harvard -- Huit ans après le lancement du projet « Vision 2030 », l’Arabie saoudite a réalisé des pas de géant en termes d’innovation numérique et d’ [...]

Pages